Result of General Meeting

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Result of General Meeting

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the General Meeting held yesterday, all resolutions were duly passed. As a result, the Directors now have authority to issue 25,000,000 (twenty-five million) new Ordinary Shares to the Placees as detailed in the Circular of this General Meeting.

Application will be made for admission to trading on AIM ("Admission") of the 25,000,000 new Ordinary Shares deriving from the Placing and it is expected that Admission will occur on or around 28 January 2019.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 194,566,092 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 194,566,092. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.